Literature DB >> 24048536

Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.

Kay A Ramsay1, Claire A Butler, Stuart Paynter, Robert S Ware, Timothy J Kidd, Claire E Wainwright, Scott C Bell.   

Abstract

Burkholderia cepacia complex organisms are important transmissible pathogens found in cystic fibrosis (CF) patients. In recent years, the rates of cross-infection of epidemic strains have declined due to effective infection control efforts. However, cases of sporadic B. cepacia complex infection continue to occur in some centers. The acquisition pathways and clinical outcomes of sporadic B. cepacia complex infection are unclear. We sought to determine the patient clinical characteristics, outcomes, incidence, and genotypic relatedness for all cases of B. cepacia complex infection at two CF centers. We also sought to study the external conditions that influence the acquisition of infection. From 2001 to 2011, 67 individual organisms were cultured from the respiratory samples of 64 patients. Sixty-five percent of the patients were adults, in whom chronic infections were more common (68%) (P = 0.006). The incidence of B. cepacia complex infection increased by a mean of 12% (95% confidence interval [CI], 3 to 23%) per year. The rates of transplantation and death were similar in the incident cases who developed chronic infection compared to those in patients with chronic Pseudomonas aeruginosa infection. Multilocus sequence typing revealed 50 individual strains from 65 isolates. Overall, 85% of the patients were infected with unique strains, suggesting sporadic acquisition of infection. The yearly incidence of nonepidemic B. cepacia complex infection was positively correlated with the amount of rainfall in the two sites examined: subtropical Brisbane (r = 0.65, P = 0.031) and tropical Townsville (r = 0.82, P = 0.002). This study demonstrates that despite strict cohort segregation, new cases of unrelated B. cepacia complex infection continue to occur. These data also support an environmental origin of infection and suggest that climate conditions may be associated with the acquisition of B. cepacia complex infections.

Entities:  

Mesh:

Year:  2013        PMID: 24048536      PMCID: PMC3838027          DOI: 10.1128/JCM.01360-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia.

Authors:  Peter M Hopkins; Timothy J Kidd; Chris Coulter; Iain H Feather; Petra Derrington; Scott C Bell
Journal:  Am J Respir Crit Care Med       Date:  2009-02-01       Impact factor: 21.405

Review 2.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Cystic fibrosis in Australia, 2009: results from a data registry.

Authors:  Scott C Bell; Peter T P Bye; Peter J Cooper; A James Martin; Karen O McKay; Phillip J Robinson; Gerard F Ryan; Geoff C Sims
Journal:  Med J Aust       Date:  2011-10-03       Impact factor: 7.738

4.  Expanded multilocus sequence typing for burkholderia species.

Authors:  Theodore Spilker; Adam Baldwin; Amy Bumford; Chris G Dowson; Eshwar Mahenthiralingam; John J LiPuma
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

5.  Geographical differences in first acquisition of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Sarath C Ranganathan; Billy Skoric; Kay A Ramsay; Rosemary Carzino; Anne-Marie Gibson; Emily Hart; Jo Harrison; Scott C Bell; Timothy J Kidd
Journal:  Ann Am Thorac Soc       Date:  2013-04

6.  Pseudomonas aeruginosa exhibits frequent recombination, but only a limited association between genotype and ecological setting.

Authors:  Timothy J Kidd; Stephen R Ritchie; Kay A Ramsay; Keith Grimwood; Scott C Bell; Paul B Rainey
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

7.  BIGSdb: Scalable analysis of bacterial genome variation at the population level.

Authors:  Keith A Jolley; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2010-12-10       Impact factor: 3.169

8.  Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study.

Authors:  Joseph M Collaco; John McGready; Deanna M Green; Kathleen M Naughton; Christopher P Watson; Timothy Shields; Scott C Bell; Claire E Wainwright; Garry R Cutting
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

9.  Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?

Authors:  Alex Horsley; Kevin Webb; Rowland Bright-Thomas; John Govan; Andrew Jones
Journal:  Front Cell Infect Microbiol       Date:  2011-12-21       Impact factor: 5.293

10.  Long-term colonization of the cystic fibrosis lung by Burkholderia cepacia complex bacteria: epidemiology, clonal variation, and genome-wide expression alterations.

Authors:  Carla P Coutinho; Sandra C Dos Santos; Andreia Madeira; Nuno P Mira; Ana S Moreira; Isabel Sá-Correia
Journal:  Front Cell Infect Microbiol       Date:  2011-12-02       Impact factor: 5.293

View more
  13 in total

1.  In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018.

Authors:  Robert K Flamm; Dee Shortridge; Mariana Castanheira; Helio S Sader; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.

Authors:  Ana S Ferreira; Inês N Silva; Fábio Fernandes; Ruth Pilkington; Máire Callaghan; Siobhán McClean; Leonilde M Moreira
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

Review 3.  Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.

Authors:  Peera Hemarajata; Jonathan D Baghdadi; Risa Hoffman; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

4.  Druggable Allosteric Sites in β-Propeller Lectins.

Authors:  Elena Shanina; Sakonwan Kuhaudomlarp; Kanhaya Lal; Peter H Seeberger; Anne Imberty; Christoph Rademacher
Journal:  Angew Chem Int Ed Engl       Date:  2021-11-23       Impact factor: 16.823

5.  Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.

Authors:  Bryan A Garcia; Jacque L Carden; Dana L Goodwin; Tim A Smith; Amit Gaggar; Kevin Leon; Veena B Antony; Steven M Rowe; George M Solomon
Journal:  BMC Pulm Med       Date:  2018-02-14       Impact factor: 3.317

6.  Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study.

Authors:  Vianney Gruzelle; Hélène Guet-Revillet; Christine Segonds; Stéphanie Bui; Julie Macey; Raphaël Chiron; Marine Michelet; Marlène Murris-Espin; Marie Mittaine
Journal:  BMC Pulm Med       Date:  2020-06-05       Impact factor: 3.317

Review 7.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

8.  Antimicrobial Activity of Monoramnholipids Produced by Bacterial Strains Isolated from the Ross Sea (Antarctica).

Authors:  Pietro Tedesco; Isabel Maida; Fortunato Palma Esposito; Emiliana Tortorella; Karolina Subko; Chidinma Christiana Ezeofor; Ying Zhang; Jioji Tabudravu; Marcel Jaspars; Renato Fani; Donatella de Pascale
Journal:  Mar Drugs       Date:  2016-04-26       Impact factor: 5.118

9.  Investigating the Role of the Host Multidrug Resistance Associated Protein Transporter Family in Burkholderia cepacia Complex Pathogenicity Using a Caenorhabditis elegans Infection Model.

Authors:  Pietro Tedesco; Marco Visone; Ermenegilda Parrilli; Maria Luisa Tutino; Elena Perrin; Isabel Maida; Renato Fani; Francesco Ballestriero; Radleigh Santos; Clemencia Pinilla; Elia Di Schiavi; George Tegos; Donatella de Pascale
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

10.  Antimicrobial activity of essential oils against multidrug-resistant clinical isolates of the Burkholderia cepacia complex.

Authors:  Lakshmi Vasireddy; Lewis E H Bingle; Mark S Davies
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.